Skip to content

René Zeiss

3 papers in the library · 20 citations · publishing 2021-2024

Papers

Sort Most recent Most cited

Case report: two cases of rhabdomyolysis following esketamine treatment.

Frontiers in Psychiatry 2024 René Zeiss, Melissa Schweizer, Bernhard J. Connemann et al. 3 citations

Major depressive disorder is a mental disorder affecting millions of people worldwide. A considerable proportion of patients demonstrate a lack of response to conventional treatment. With the recent introduction of esketamine, a new treatment option has been approved for treatment-resistant depression. Although the medication is efficacious in a substantial portion of cases, rare, but possibly...

Psilocybin as an antidepressant strategy - a review of safety aspects

European Psychiatry March 1, 2023 René Zeiss

Introduction Psilocybin is considered a classical psychedelic and is increasingly attracting scientific and media attention as an alternative approach to the treatment of various mental disorders. Apart from its efficacy, an important question is the tolerability and safety of psilocybin in general and in a controlled environment. Accurate knowledge of drug safety aspects might be essential for...

Rediscovering Psilocybin as an Antidepressive Treatment Strategy

Pharmaceuticals September 28, 2021 René Zeiss, Maximilian Gahr, Heiko Graf 17 citations

There has recently been a renewal of interest in psychedelic research on the use of psilocybin in psychiatric treatment and, in particular, for the treatment of major depressive disorder (MDD). Several state-of-the-art studies have provided new insight into the mechanisms of action of psilocybin and its therapeutic potential. Nevertheless, many questions remain unanswered. With this review, we...